Delivery Order SPE2DB24D2106-SPE2DB25FAWML
- Not listed
- The Defense Logistics Agency awarded a $16.8K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300 mg pen injections. The order, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed-price delivery under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million and valid through November...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,169.67 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, on September 10, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order covers the supply of Cosentyx (secukinumab) 300mg dose in 2-pen packages, with performance to be executed in Conshohocken, Pennsylvania. The contract was awarded without a set-aside designation, allowing the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois, received a delivery order valued at $23.5K from the Defense Logistics Agency (DLA) on June 16, 2025, for Cosentyx (secukinumab) 300mg dose in 2-pen/mL format. This firm fixed-price delivery order, with an ultimate completion date of June 17, 2025, was awarded without set-aside designation and will be performed in Conshohocken, Pennsylvania. The award falls under DMS Pharmaceutical Group's...
- On June 2, 2025, the Defense Logistics Agency awarded a firm fixed-price delivery order valued at $9,807.94 to DMS Pharmaceutical Group Inc. for the supply of Cosentyx (secukinumab) 300mg dose-2 pen/ml. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order with performance at its Conshohocken, Pennsylvania location. The award carries no set-aside designation, and the delivery order is scheduled for ultimate...
- The Defense Logistics Agency awarded a $19,259.62 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose-2 pen/ml pharmaceutical products. The delivery order, issued on September 11, 2025, with an ultimate completion date of September 12, 2025, does not utilize a set-aside designation. Performance will be executed in Conshohocken, Pennsylvania. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park...
- The Defense Logistics Agency awarded a delivery order valued at $13,735.58 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2-pen/mL formulation on August 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a pharmaceutical supply requirement with performance taking place in Conshohocken, Pennsylvania. The award was made without set-aside designation to DMS Pharmaceutical Group, a woman-owned small business...
- The Defense Logistics Agency awarded a $50,400.96 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300 mg pen 2 mL injections on September 10, 2025, with completion targeted for September 11, 2025. This delivery order was issued without set-aside designation and is being fulfilled from the contractor's place of business in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is supplying this...
- On August 20, 2025, the Defense Logistics Agency awarded a delivery order valued at $10,461.10 to DMS Pharmaceutical Group Inc. for the supply of Cosentyx (secukinumab) 300 mg pen 2 mL injections. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract does not utilize a set-aside designation, and the pharmaceutical products will be...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $3,382.36 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of COSENTYX UNOREADY 300 MG PEN 2ML, a pharmaceutical product, to support the recurring medical supply needs of military health facilities worldwide. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical...
- The Defense Logistics Agency awarded a $8,935.09 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2 pen/mL formulation on September 8, 2025, with an ultimate completion date of September 9, 2025. This award carries no set-aside designation and represents performance at the vendor's location in Conshohocken, Pennsylvania. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, is...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB25FAWMLDelivery Order
The Defense Logistics Agency (DLA) awarded a $5,015.29 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300mg dose injections. This firm fixed-price delivery order, awarded on September 16, 2025, with an ultimate completion date of September 17, 2025, represents a single-unit pharmaceutical procurement with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, supporting the Defense Department's pharmaceutical supply needs. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion contract vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products for military health facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its woman-owned small business status to compete effectively in DLA procurement markets. The company's portfolio demonstrates consistent success in delivering specialty medications, biologics, and medical consumables across various therapeutic categories to support Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 9/16/25 |